Geron Corporation - Common Stock (GERN)
0.9898
+0.0397 (4.18%)
NASDAQ · Last Trade: Nov 7th, 5:22 AM EST
News & Press Releases
Geron: 3 Key Takeaways for Long-Term Investorsfool.com
Operating expenses fell 9% year to date, and $339 million in cash leaves Geron room to pursue hematology deals.
Via The Motley Fool · November 5, 2026
Geron Corp (GERN) Q3 2026 Earnings Call Transcriptfool.com
First profit as a commercial-stage biotech, on RYTELO growth and cost cuts.
Via The Motley Fool · November 4, 2026
Geron Q3 Earnings Call Highlightsmarketbeat.com
Geron (NASDAQ:GERN) reported third-quarter net product revenue of $60.1 million for RYTELO, a 27% increase from $47.2 million a year earlier, as the company cited continued growth in prescribing, particularly among community practices.
Chief Executive Officer Harout Semerjian said RYTELO demand inc
Via MarketBeat · November 4, 2026
Geron (NASDAQ:GERN) Falls After Mixed Q2 Results; Revenue Beats but Loss Wider Than Expectedchartmill.com
Via Chartmill · August 5, 2026
Geron Corp. (NASDAQ:GERN) Beats Q1 Estimates as RYTELO Sales Momentum Continueschartmill.com
Via Chartmill · May 6, 2026
Geron Corp (NASDAQ:GERN) Stock Plummets 10% After Q4 Revenue Misschartmill.com
Via Chartmill · February 25, 2026
Most Active Stocks in the 2026-10-28 US Sessionchartmill.com
Via Chartmill · October 28, 2026
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Geron Corporation (“Geron” or the “Company”) (NasdaqGS: GERN).
By Kahn Swick & Foti, LLC · Via Business Wire · October 12, 2026
Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine
Via FinancialNewsMedia · September 30, 2026
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expandsmarketbeat.com
Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $
Via MarketBeat · September 16, 2026
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Geron Corporation (“Geron” or the “Company”) (NasdaqGS: GERN).
By Kahn Swick & Foti, LLC · Via Business Wire · September 14, 2026
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expandsmarketbeat.com
Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS.
Dur
Via MarketBeat · September 13, 2026
Geron (GERN) Q2 2026 Earnings Call Transcriptfool.com
RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch.
Via The Motley Fool · August 6, 2026
Geron Q2 Earnings Call Highlightsmarketbeat.com
Geron (NASDAQ:GERN) reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with lower-risk myelodysplastic syndromes, or MDS.
Chief Executive Officer Harout Semerjian said first-half net
Via MarketBeat · August 5, 2026
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END
Via FinancialNewsMedia · May 20, 2026
Geron (GERN) Q1 2026 Earnings Call Transcriptfool.com
Geron (GERN) Q1 2026 Earnings Call Transcript
Via The Motley Fool · May 7, 2026
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END
Via FinancialNewsMedia · March 3, 2026
Here are the top movers in Wednesday's session.chartmill.com
Via Chartmill · February 25, 2026
Geron (GERN) Q4 2025 Earnings Call Transcriptfool.com
Geron (GERN) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 25, 2026
Which stocks are moving before the opening bell on Wednesday?chartmill.com
Via Chartmill · February 25, 2026
Why Did GERN Stock Tumble 10% Pre-Market Today?stocktwits.com
Total revenue reached $48 million for the fourth-quarter with a loss per share (EPS) of $0.05, with both metrics coming in below street estimates.
Via Stocktwits · February 25, 2026
Geron Corp (NASDAQ:GERN) Reports Mixed Q3 2025 Results, Misses Revenue Estimateschartmill.com
Geron's Q3 2025 results show mixed performance, with RYTELO revenue up 67% year-over-year but missing analyst sales estimates, causing a negative market reaction.
Via Chartmill · November 5, 2025
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights.
By Geron Corporation · Via Business Wire · November 5, 2025